Modeling and predicting tumor response in radioligand therapy
P Kletting, A Thieme, N Eberhardt… - Journal of nuclear …, 2019 - Soc Nuclear Med
The aim of this work was to develop a theranostic method that allows prediction of prostate-
specific membrane antigen (PSMA)–positive tumor volume after radioligand therapy (RLT) …
specific membrane antigen (PSMA)–positive tumor volume after radioligand therapy (RLT) …
[HTML][HTML] Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with 177Lu-PSMA I&T therapy
Purpose Although treatment planning and individualized dose application for emerging
prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) are …
prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) are …
Prognostic value of tumor volume assessment on PSMA PET after 177Lu-PSMA radioligand therapy evaluated by PSMA PET/CT consensus statement and RECIP 1.0
F Kind, AC Eder, CA Jilg, PE Hartrampf… - Journal of Nuclear …, 2023 - Soc Nuclear Med
Quantitative evaluation of prostate-specific membrane antigen (PSMA)–targeting PET/CT
remains challenging but is urgently needed for the use of standardized PET-based response …
remains challenging but is urgently needed for the use of standardized PET-based response …
Determination of whole-body tumour burden on [68Ga] PSMA-11 PET/CT for response assessment of [177Lu] PSMA-617 radioligand therapy: a retrospective analysis …
Aim In patients with metastasized castration-resistant prostate cancer a reliable imaging-
based therapy response assessment in addition to PSA kinetics is desirable. Recently …
based therapy response assessment in addition to PSA kinetics is desirable. Recently …
[HTML][HTML] PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric …
R Seifert, K Kessel, K Schlack, M Weber… - European Journal of …, 2021 - Springer
Abstract Introduction [177 Lu] Lu-PSMA-617 (Lu-PSMA) radioligand therapy is an emerging
treatment option for patients with end-stage prostate cancer. However, response to Lu …
treatment option for patients with end-stage prostate cancer. However, response to Lu …
Radiation dosimetry in 177Lu-PSMA-617 therapy using a single posttreatment SPECT/CT scan: a novel methodology to generate time-and tissue-specific dose factors
Calculation of radiation dosimetry in targeted nuclear medicine therapies is traditionally
resource-intensive, requiring multiple posttherapy SPECT acquisitions. An alternative …
resource-intensive, requiring multiple posttherapy SPECT acquisitions. An alternative …
Voxel-wise prediction of post-therapy dosimetry for 177Lu-PSMA I&T therapy using deep learning
1424 Introduction: PSMA-directed radioligand therapy (RLT) has become one of the
effective treatment options for metastatic castration-resistant prostate cancer (mCRPC) …
effective treatment options for metastatic castration-resistant prostate cancer (mCRPC) …
Radiation dosimetry for 177Lu-PSMA I&T in metastatic castration-resistant prostate cancer: absorbed dose in normal organs and tumor lesions
S Okamoto, A Thieme, J Allmann… - Journal of Nuclear …, 2017 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA)–targeted radioligand therapy is increasingly
used in metastatic castration-resistant prostate cancer. We aimed to estimate the absorbed …
used in metastatic castration-resistant prostate cancer. We aimed to estimate the absorbed …
[HTML][HTML] The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model
The aim of this work was to investigate the effect of ligand amount, affinity and internalization
of prostate-specific membrane antigen (PSMA)-specific ligands on the activity …
of prostate-specific membrane antigen (PSMA)-specific ligands on the activity …
[HTML][HTML] Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after 177Lu-PSMA-617 Radioligand Therapy
F Völter, L Mittlmeier, A Gosewisch, J Brosch-Lenz… - Diagnostics, 2021 - mdpi.com
Background: Dosimetry can tailor prostate-specific membrane-antigen-targeted radioligand
therapy (PSMA-RLT) for metastatic castration-resistant prostate cancer (mCRPC). However …
therapy (PSMA-RLT) for metastatic castration-resistant prostate cancer (mCRPC). However …
Related searches
- tumor response radioligand therapy
- 177lu psma radioligand therapy
- prostate cancer radioligand therapy
- outcome of patients radioligand therapy
- recip 1.0 radioligand therapy
- bicentric analysis radioligand therapy
- consensus statement radioligand therapy
- prognostic value radioligand therapy
- index lesion radioligand therapy
- 177lu psma prostate cancer
- outcome of patients prostate cancer
- 177lu psma radiation dosimetry
- 177lu psma tumor volume assessment
- prostate cancer tumor lesions
- 177lu psma recip 1.0
- 177lu psma dose factors